DOCSLIB.ORG

Veyres N, Hamadjida A, Huot P. Predictive Value of Parkinsonian Primates in Pharmacological Studies, a Comparison Between the Macaque, Marmoset and Squirrel Monkey

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Veyres N, Hamadjida A, Huot P. Predictive Value of Parkinsonian Primates in Pharmacological Studies, a Comparison Between the Macaque, Marmoset and Squirrel Monkey Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther Table S1: pharmacological profile of the drugs assessed in the MPTP-lesioned primate drug mechanism of action category references D-(9)-THC cannabinoid (Felder et al., CB1,2 agonist (dronabinol) agonist 1995) (-)-3-(3- (Arnt et al., hydroxyphenyl)-N-n- D2 agonist, s ligand D2 agonist 1983; Iyengar et propylpiperone al., 1991) (+)-4-propyl-9- (Martin et al., hydroxynaphthoxazine D2 agonist, a2 ligand D2 agonist 1985) (PHNO) (+)-N-n-propyl-3-(3- (Close et al., hydroxyphenyl)- D2 agonist D2 agonist 1990) piperidine [(+)-3PPP] (-)-N-n-propyl-3-(3- (Close et al., hydroxyphenyl)- D2 partial agonist D2 partial agonist 1990) piperidine (-)-3PPP (Loschmann et (-)-N-0437 D2-like agonist D2 agonist al., 1989) (Burstein et al., (-)-OSU-6162 (PNU- D2 partial agonist, 5-HT2A D2 partial agonist 2011; Carlsson 96,391) partial agonist et al., 2011) 2-amino-5,6- (Mulder et al., D2 agonist D2 agonist dihydroxytetralin 1980; Gower 1 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (N,N-dipropyl A-5,6- and Marriott, DTN) 1982) (Tricklebank et 5-MDOT (5-MeO- non-selective 5-HT al., 1985; 5-HT agonist DMT) receptor agonist Spencer et al., 1987) (Lejeune et al., 8-OH-DPAT 5-HT1A agonist 5-HT1A agonist 1997) 17-alpha-oestradiol oestrogen receptor agonist, (Kuiper et al., oestrogen agonist (alfatradiol) 5a-reductase inhibitor 1997) (Kuiper et al., 17-beta-oestradiol oestrogen receptor agonist oestrogen agonist 1997) (Vanover et al., A-66,359 D1 antagonist D1 antagonist 1991) (Kebabian et al., A-77,636 D1 agonist D1 agonist 1992) (Michaelides et al., 1995; A-86,929 D1 agonist D1 agonist Ehrlich et al., 1997) (Marks et al., ABT-089 (pozanicline) b2 nACh agonist nicotinic agonist 2009) 2 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Malysz et al., ABT-107 a7 nACh agonist nicotinic agonist 2010) (Zhang et al., ABT-126 (nelonicline) a7 nACh agonist nicotinic agonist 2015; Haig et al., 2016) (Shiosaki et al., ABT-431 (adrogolide) D1 agonist D1 agonist 1996) ABT-894 (sofinicline) a4b2 nACh agonist nicotinic agonist (Ji et al., 2007) (Koprich et al., ADL-5510 µ antagonist µ antagonist 2011) AFQ-056 (Vranesic et al., mGlu5 NAM mGlu5 NAM (mavoglurant) 2014) (Matsubayashi NMDA antagonist, s1 et al., 1997; amantadine agonist, a7 nACh NMDA antagonist Peeters et al., antagonist 2004; Blanpied et al., 2005) (Schlicker et al., anpirtoline 5-HT1B > 5-HT1A agonist 5-HT1B agonist 1992) dopamine partial (Heinrich et al., aplindore (DAB-452) D2,3 partial agonist agonist 2006) D1 agonist, D2,3,4 partial (Millan et al., apomorphine dopamine agonist agonist, 5-HT2A,2B,2C 2002; Newman- 3 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther antagonist, 5-HT1A partial Tancredi et al., agonist, a2A partial agonist, 2002a; a2B,2C antagonist Newman- Tancredi et al., 2002b) nicotinic partial (Feuerbach et AQW-051 a7 nACh partial agonist agonist al., 2015) muscarinic (Hirose et al., atropine M1,2,3,4,5 antagonist antagonist 2001) (Hirst et al., baclofen GABAB agonist GABAB agonist 2003) benztropine M1,2 antagonist, DAT muscarinic (Newman et al., (benzatropine) inhibitor antagonist 1995) (Bezard et al., BP-897 D3 partial agonist D3 partial agonist 2003; Pilleri and Antonini, 2015) non-selective brasofensine (NS-2214, DAT, NET, SERT monoamine re- (Singh, 2000) BMS-204,756) inhibitor uptake inhibitor D2,3-preferential dopamine bromocriptine (CB- agonist, 5-HT1A,1D partial (Millan et al., dopamine agonist 154) agonist, a2A,2B,2C 2002) antagonist 4 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther non-selective (Cheetham et DAT, NET, SERT BTS-74,398 monoamine re- al., 1998; Singh, inhibitor uptake inhibitor 2000) (Carroll et al., dual monoamine bupropion DAT, NET inhibitor 2009; Lapinsky re-uptake inhibitor et al., 2009) D2,3 partial agonist, 5- (Millan et al., cabergoline HT1A,1D,2A,2B agonist, dopamine agonist 2002) a2A,2C antagonist cannabinoid (Cao et al., CE CB1 antagonist antagonist 2007) (Ben-Daniel et citalopram SERT inhibitor SERT inhibitor al., 2008) (Barton and CI-1041 (besonprodil, White, 2004; PD-196,860, Co- NR2B antagonist NMDA antagonist Barton et al., 200,461) 2004) (Ernsberger et clonidine a2A,2B,2C agonist, I1 agonist a2 agonist al., 1987; Jasper et al., 1998) H1 antagonist, 5- (Lahti et al., atypical anti- clozapine HT2A,2B,2C,6,7 antagonist, 1993; Schotte et psychotic a1A,1B,1D antagonist, D4 al., 1996; 5 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther antagonist, 5-HT1A,1F Yoshio et al., agonist 2001; Booth et al., 2002; Knight et al., 2004; Purohit et al., 2005) D2 fast-off (Koprich et al., CLR-151 D2 antagonist antagonist 2013) Co-101,244/PD- (Gill et al., NR2B antagonist NMDA antagonist 174,494 (Ro-631,908) 2002) (Koe et al., CP-94,253 5-HT1B-preferential agonist 5-HT1B agonist 1992) (Chenard et al., CP-101,606 1995; NR2B antagonist NMDA antagonist (traxoprodil) Brimecombe et al., 1997) (Feng et al., CPP NR2A,2B,2C,2D antagonist NMDA antagonist 2004) (Krintel et al., CX-516 (BDP-12) GluA2 PAM AMPAkine 2013) (Andersen and CY-208,243 D1,2 agonist dopamine agonist Jansen, 1990) 6 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther 5-HT2A,2C,6,7 antagonist, H1 (Leysen et al., cyproheptadine antagonist, a1B,1D 5-HT antagonist 1981; Hoyer et antagonist al., 1994) (Bergeron et al., androgen receptor agonist, 1996; Maurice a- and b-oestrogen et al., 1997; DHEA receptor agonist, GABAA androgen agonist Sousa and NAM, NMDA PAM, s1 Ticku, 1997; agonist Chen et al., 2005) (Pritchett et al., diazepam GABAA PAM GABAA PAM 1989) dipraglurant (ADX- (Chae et al., mGlu5 NAM mGlu5 NAM 48,621) 2013) (Lampen et al., 2001; Itoh et al., FFA1 agonist, RXR-a docosahexaenoic acid RXR agonist 2003; Motter agonist, TRPA1 agonist and Ahern, 2012) eltoprazine (DU- 5-HT1A,1B agonist, 5-HT2C (Schipper et al., 5-HT1A,1B agonist 28,853) antagonist 1990) (Lotta et al., entacapone (OR-611) COMT inhibitor COMT inhibitor 1995) 7 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther T-type calcium channel T-type calcium (Gomora et al., ethosuximide antagonist channel antagonist 2001) (Newman- preferential post-synaptic F-15,599 5-HT1A agonist Tancredi et al., 5-HT1A agonist 2009) famotidine H2 antagonist H2 antagonist (Chremos, 1987) (Porter et al., fenobam mGlu5 NAM mGlu5 NAM 2005) (Johnston et al., fipamezole (JP-1730) a2A,2B,2C antagonist a2 antagonist 2010) GBR-12,909 (Andersen, DAT inhibitor DAT inhibitor (vanoxerine) 1989) (Abraham et al., GYKI-47,261 AMPA antagonist AMPA antagonist 2000) (Sunahara et al., D2-like antagonist, D1 1991; Tice et al., haloperidol antagonist, a1 antagonist, D2 antagonist 1994; Kroeze et s1 antagonist al., 2003; Cobos et al., 2007) (Doxey et al., 1984; idazoxan a2 antagonist, I2 agonist a2 antagonist Regunathan and Reis, 1996) 8 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Schlesinger et IEM-1460 AMPA antagonist AMPA antagonist al., 2005) (Reynolds and Miller, 1989; ifenprodil NR1,2 antagonist NMDA antagonist Korinek et al., 2011) (Garbarg et al., imetit H3,4 agonist H3,4 agonist 1992; Liu et al., 2001) (Liu et al., 2001; immepip H3,4 agonist H3,4 agonist Kitbunnadaj et al., 2003) istradefylline (KW- (Fredholm et al., A2A antagonist A2A antagonist 6002) 2011) (Kawamoto et J-113,397 ORL-1 antagonist ORL-1 antagonist al., 1999; Ozaki et al., 2000) dopamine (Liegeois et al., JL-18 D2,4 antagonist antagonist 1995) (Philippens et JNJ-27,063,699 a2C antagonist a2 antagonist al., 2014) (Patel et al., L-745,870 D4 antagonist D4 antagonist 1997) 9 Veyres N, Hamadjida A, Huot P. Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey. J Pharmacol Exp Ther (Fernstrom, L-tryptophan 5-HT precursor 5-HT agonist 1983) (Lynch et al., levetiracetam SV2A antagonist SV2A antagonist 2004) (Tsuruta et al., LY-141,865 D2 agonist D2 agonist 1981) (Schoepp et al., LY-235,959 (active NMDA antagonist NMDA antagonist 1991; Herman et isomer of LY-274,614) al., 1995) NR2A-preferential (Blanchet et al., MDL-100,453 NMDA antagonist antagonist 1999) (Battaglia et al., DAT inhibitor, SERT 1988; Nash et dual monoamine MDMA inhibitor, 5-HT2A partial al., 1994; re-uptake inhibitor agonist Verrico et al., 2007) melanocyte-inhibiting factor (Pro-Leu-Gly- (Verma et al., NH2, melanostatin, D2,4 PAM, opiate D2 PAM 2005; Pan and MSH release- antagonist Kastin, 2007) inhibiting
Load more

Recommended publications
  • Inhibition of 50-Khz Ultrasonic Vocalizations by Dopamine Receptor Subtype-Selective Agonists and Antagonists in Adult Rats
    Psychopharmacology (2013) 226:589–600 DOI 10.1007/s00213-012-2931-6 ORIGINAL INVESTIGATION Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats Tina Scardochio & Paul B. S. Clarke Received: 6 September 2012 /Accepted: 13 November 2012 /Published online: 29 November 2012 # Springer-Verlag Berlin Heidelberg 2012 Abstract calling. The D4 agonist and antagonist did not significantly Rationale Adult rats emit ultrasonic calls at around 22 and affect 50-kHz call rates. Twenty-two-kilohertz calls oc- 50 kHz, which are often elicited by aversive and rewarding curred infrequently under all drug conditions. stimuli, respectively. Dopamine (DA) plays a role in aspects Conclusion Following systemic drug administration, tonic of both reward and aversion. pharmacological activation of D1-like or D2-like DA recep- Objective The purpose of this study is to investigate the tors, either alone or in combination, does not appear suffi- effects of DA receptor subtype-selective agonists on 22- cient to induce 50-kHz calls. Dopaminergic transmission and 50-kHz call rates. through D1, D2, and D3 receptors appears necessary for Methods Ultrasonic calls were recorded in adult male rats spontaneous calling. that were initially screened with amphetamine to eliminate low 50-kHz callers. The remaining subjects were tested after Keywords Vocalization . Dopamine receptor . Reward . acute intraperitoneal or subcutaneous injection of the fol- Aversion . Agonist . Antagonist . Reinforcement . lowing DA receptor-selective agonists and antagonists: Behavior . D1 [D-1] . D2 [D-2] A68930 (D1-like agonist), quinpirole (D2-like agonist), PD 128907 (D3 agonist), PD 168077 (D4 agonist), SCH 39166 (D1-like antagonist), L-741,626 (D2 antagonist), Introduction NGB 2904 (D3 antagonist), and L-745,870 (D4 antagonist).
    [Show full text]
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green Et Al
    US009381189B2 (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green et al. (45) Date of Patent: Jul. 5, 2016 (54) INGREDIENTS FOR INHALATION AND (56) References Cited METHODS FOR MAKING THE SAME U.S. PATENT DOCUMENTS (75) Inventors: Matthew Michael James Green, 4,582,265 A * 4/1986 Petronelli ....................... 241.95 Wiltshire (GB); Richard Michael Poole, 6,257,233 B1 7/2001 Burr et al. 2004/01 18007 A1* 6/2004 Chickering et al. ............ 34/360 Wiltshire (GB) 2006, O257491 A1* 11, 2006 Morton et al. ... 424/489 (73) Assignee: VECTURA LIMITED, Wiltshire (GB) 2008/0063719 A1 3/2008 Morton et al. ................ 424/489 (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 EP O709086 A2 5, 1996 U.S.C. 154(b) by 641 days. EP 14981 16 A1 1, 2005 GB 2387781 A 10, 2003 JP 2005298.347 10/2005 (21) Appl. No.: 13/514,672 JP 200954.1393 11, 2009 JP 2012,542618 6, 2012 (22) PCT Fled: Dec. 8, 2010 WO 96.23485 A1 8, 1996 WO 9703649 A1 2, 1997 (86) PCT NO.: PCT/GB2O10/052053 WO O2OO197 A1 1, 2002 WO O243701 A2 6, 2002 S371 (c)(1), WO 2005105043 A2 11/2005 Aug. 20, 2012 WO 2007053904 A1 5/2007 (2), (4) Date: WO 2008.000482 1, 2008 (87) PCT Pub. No.: WO2O11AO70361 WO 2009095684 A1 8, 2009 OTHER PUBLICATIONS PCT Pub. Date: Jun. 16, 2011 Brunauer et al. "Adsorption of Gases in Multimolecular Layers'. J. (65) Prior Publication Data Am.
    [Show full text]
  • Xenoport Hurt by Solzira NDA Withdrawal
    November 11, 2008 Xenoport hurt by Solzira NDA withdrawal Evaluate Vantage News that Xenoport and partner GlaxoSmithKline’s recent application for restless legs syndrome (RLS) drug Solzira will have to be withdrawn, with the FDA requesting that data from a single trial be re-formatted, caused Xenoport’s shares to fall 13% yesterday to a new 18-month low of $34.44. With a potential 4-6 month delay to approval and the postponement of a $23m milestone that Xenoport was due to receive from Glaxo on the FDA’s acceptance of Solzira’s NDA, senior executives at the specialty US company could be forgiven for feeling somewhat aggrieved with Glaxo for this apparent oversight, given the pharma giant’s supposed experience and expertise in regulatory filings. The setback to Solzira and resulting slump in Xenoport’s share price suggests that shareholders who have not fled the stock will be even more desperate for positive phase IIb data for GERD treatment, XP19986 (Event - XenoPort looking for end of year trial lift, October 10, 2008). Formatting issues Avoiding these kinds of regulatory pitfalls, after all the cost and hard work involved in taking a drug through clinical development, is becoming an increasingly important factor behind a company’s decision to sign up a big pharma partner in today’s tougher regulatory environment. Both companies were naturally keen to stress that the NDA withdrawal has nothing to do with the content of the filing, which probably makes the rejection on a technicality all the more frustrating for Xenoport. Whilst the FDA requested the data from one particular study to be re-formatted, Glaxo has decided to review the formatting of other data sets in the application, presumably to ensure there can be no further grounds for rejection.
    [Show full text]
  • Sex Differences in Nicotine-Conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes
    East Tennessee State University Digital Commons @ East Tennessee State University Electronic Theses and Dissertations Student Works 8-2008 Sex Differences in Nicotine-Conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes. Ashley Brianna Sheppard East Tennessee State University Follow this and additional works at: https://dc.etsu.edu/etd Part of the Hormones, Hormone Substitutes, and Hormone Antagonists Commons Recommended Citation Sheppard, Ashley Brianna, "Sex Differences in Nicotine-Conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes." (2008). Electronic Theses and Dissertations. Paper 1978. https://dc.etsu.edu/etd/ 1978 This Thesis - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State University. For more information, please contact [email protected]. Sex Differences in Nicotine-conditioned Hyperactivity in a Model of Dopamine D2 Receptor Priming: Roles of Dopamine D2 and D3 Receptor Subtypes A thesis presented to the faculty of the Department of Psychology East Tennessee State University In partial fulfillment of the requirements for the degree of Master of Arts in Psychology by Ashley Brianna Sheppard August 2008 Russell Brown, PhD., Chair Michael Woodruff, PhD., Committee member Otto Zinser,
    [Show full text]
  • Apo-Ropinirole
    New Zealand Data Sheet APO-ROPINIROLE 1. PRODUCT NAME APO-ROPINIROLE 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg and 5mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ropinirole hydrochloride 0.25mg Ropinirole hydrochloride 0.5mg Ropinirole hydrochloride 1mg Ropinirole hydrochloride 2mg Ropinirole hydrochloride 3mg Ropinirole hydrochloride 4mg Ropinirole hydrochloride 5mg Excipient(s) with known effect Contains lactose. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM APO-ROPINIROLE is available as oral, film coated tablets in the following strengths: APO-ROPINIROLE 0.25mg tablets are white, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “.25” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 0.5mg tablets are yellow, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “.5” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 1mg tablets are green, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “1” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 2mg tablets are pink, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “2” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 3mg tablets are purple, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “3” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 4mg tablets are pale brown, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “4” on one side and “APO’ on the other side.
    [Show full text]
  • Metabolism and Pharmacokinetics in the Development of New Therapeutics for Cocaine and Opioid Abuse
    University of Mississippi eGrove Electronic Theses and Dissertations Graduate School 2012 Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse Pradeep Kumar Vuppala University of Mississippi Follow this and additional works at: https://egrove.olemiss.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Vuppala, Pradeep Kumar, "Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse" (2012). Electronic Theses and Dissertations. 731. https://egrove.olemiss.edu/etd/731 This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information, please contact [email protected]. METABOLISM AND PHARMACOKINETICS IN THE DEVELOPMENT OF NEW THERAPEUTICS FOR COCAINE AND OPIOID ABUSE A Dissertation presented in partial fulfillment of requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences in the Department of Pharmaceutics The University of Mississippi by PRADEEP KUMAR VUPPALA April 2012 Copyright © 2012 by Pradeep Kumar Vuppala All rights reserved ABSTRACT Cocaine and opioid abuse are a major public health concern and the cause of significant morbidity and mortality worldwide. The development of effective medication for cocaine and opioid abuse is necessary to reduce the impact of this issue upon the individual and society. The pharmacologic treatment for drug abuse has been based on one of the following strategies: agonist substitution, antagonist treatment, or symptomatic treatment. This dissertation is focused on the role of metabolism and pharmacokinetics in the development of new pharmacotherapies, CM304 (sigma-1 receptor antagonist), mitragynine and 7-hydroxymitragynine (µ-opioid receptor agonists), for the treatment of drug abuse.
    [Show full text]
  • Alpha^ and Beta^Blocking Agents: Pharmacology and Properties
    CURRENT DRUG THERAPY DONALD G. VIDT, MD AND ALAN BAKST, PharmD, EDITORS Alpha^ and beta^blocking agents: pharmacology and properties PROFESSOR B.N.C. PRICHARD • Adrenergic receptors have been separated into alpha and beta groups, which have then been further subdivided. Agents have been developed that block each type of receptor with varying degrees of specificity between the sub-types, leading to differences in pharmacodynamic profile. A more recent innovation has been the development of multiple action beta-blocking drugs, ie, those not only blocking the beta receptors but also posessing a peripheral vasodilator effect that may be due to alpha blockade, beta-2 stimulation, or a vasodilator action independent of either alpha or beta receptors. • INDEX TERMS: ALPHA BLOCKERS; BETA BLOCKERS; HYPERTENSION • CLEVE CLIN ] MED 1991; 58:33 7-350 HE CONCEPT that binding of Rosenblueth suggested that a transmitter released at catecholamines to receptors leads to differ- sympathetic nerve endings produced either inhibitory ing responses was first described by Langley, or excitatory responses as a result of combination with who in 1905 noted that a cell may make sympathin I or sympathin E at the receptor.3 Tmotor or inhibitory substances or both, and that "the The current classification of alpha and beta respon- effect of a nerve impulse depends upon the proportion ses is based on the classic work of Ahlquist,4 who of the two kinds of receptive substance which is af- studied six sympathomimetic amines and found two fected by the impulse."1 In 1906, Dale reported that patterns of reactivity. One group of actions, mediated ergot blocked the excitatory but not the inhibitory ac- by what were termed "alpha receptors," were principally tions of adrenaline.2 In 1933, Cannon and excitatory.
    [Show full text]
  • Stimulation Du Cortex Préfrontal: Mécanismes Neurobiologiques De
    Stimulation du cortex préfrontal : Mécanismes neurobiologiques de son effet antidépresseur Adeline Etievant To cite this version: Adeline Etievant. Stimulation du cortex préfrontal : Mécanismes neurobiologiques de son effet an- tidépresseur. Médecine humaine et pathologie. Université Claude Bernard - Lyon I, 2012. Français. NNT : 2012LYO10021. tel-00865594 HAL Id: tel-00865594 https://tel.archives-ouvertes.fr/tel-00865594 Submitted on 24 Sep 2013 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Année 2012 Thèse n°021 - 2012 THESE pour le DOCTORAT DE L’UNIVERSITE CLAUDE BERNARD LYON 1 Ecole doctorale Neurosciences et Cognition Discipline : Neurosciences Soutenue publiquement 23 février 2012 Par Adeline ETIÉVANT STIMULATION DU CORTEX PREFRONTAL : Mécanismes neurobiologiques de son effet antidépresseur Membres du jury : Mr. François JOURDAN Président Mr. Bruno GUIARD Rapporteur Mr. Raymond MONGEAU Rapporteur Mme. Véronique COIZET Examinateur Mr. Bruno MILLET Examinateur M. Nasser HADDJERI Directeur de thèse REMERCIEMENT " " Lg" uqwjckvg" vqwv" f)cdqtf"
    [Show full text]
  • Nicotinic Receptors in Neurodegeneration
    Send Orders of Reprints at [email protected] 298 Current Neuropharmacology, 2013, 11, 298-314 Nicotinic Receptors in Neurodegeneration Inmaculada Posadas, Beatriz López-Hernández and Valentín Ceña* Unidad Asociada Neurodeath. CSIC-Universidad de Castilla-La Mancha, Departamento de Ciencias Médicas. Albacete, Spain and CIBERNED, Instituto de Salud Carlos III, Spain Abstract: Many studies have focused on expanding our knowledge of the structure and diversity of peripheral and central nicotinic receptors. Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of pentameric ligand-gated ion channels, which include GABA (A and C), serotonin, and glycine receptors. Currently, 9 alpha (2-10) and 3 beta (2-4) subunits have been identified in the central nervous system (CNS), and these subunits assemble to form a variety of functional nAChRs. The pentameric combination of several alpha and beta subunits leads to a great number of nicotinic receptors that vary in their properties, including their sensitivity to nicotine, permeability to calcium and propensity to desensitize. In the CNS, nAChRs play crucial roles in modulating presynaptic, postsynaptic, and extrasynaptic signaling, and have been found to be involved in a complex range of CNS disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, Tourette´s syndrome, anxiety, depression and epilepsy. Therefore, there is growing interest in the development of drugs that modulate nAChR functions with optimal benefits and minimal adverse effects. The present review describes the main characteristics of nAChRs in the CNS and focuses on the various compounds that have been tested and are currently in phase I and phase II trials for the treatment of neurodegenerative diseases including PD, AD and age-associated memory and mild cognitive impairment.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]